The U.S. Food and Drug Administration revealed in a letter to healthcare providers that it's investigating numerous medical device reports describing patient infections and other possible contamination issues potentially associated with reprocessed urological endoscopes. Dr. Larry Muscarella delves into more detail on reprocessing best practices and some of the challenges therein. He also shares his key takeaways from the FDA letter — for clinicians, regulators and healthcare consumers alike.